Anti-SARS-CoV-2 Neutralizing Antibody Responses after Two Doses of ChAdOx1 nCoV-19 vaccine (AZD1222) in Healthcare Workers
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: The kinetics of neutralizing antibodies against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) play an important role in evaluating vaccine efficacy and durability, herd immunity, additional vaccination, and prediction models of immune protection against coronavirus disease 2019. Materials and methods: Serum collection times were 4 and 8 weeks after 1st inoculation of AZD1222 (AstraZeneca, Cambridge, UK), and 2 and 16 weeks after 2nd inoculation with 12-week dosing intervals. Neutralizing antibody (Nab) titers were measured indirectly using commercially available R-FIND SARS-CoV-2 Neutralizing Antibody ELISA Kit (SG Medical Inc., Seoul, Korea). Possible influences of gender, age, and adverse events on neutralizing antibody titer were also investigated. Results: Nab titers (median inhibition %) started to decrease shortly after reaching peaks. This decrease was more pronounced in the elderly group (≥56 years) than in the young group (≤39 years) at 8 weeks (49.5% vs. 55.4%, P = 0.021) and 16 weeks (40.6% vs. 53.9%, P = 0.006) after the 1st and 2nd inoculation. And Nab titers were inversely correlated with age in the 8-week (r = -0.2091, P = 0.0284) and the 28-week group (r = -0.2811, P = 0.0029). Seropositive conversion of Nab reached 89.1% and 100% following 1st and 2nd inoculation. This 100% seropositivity was dropped sharply to 74.5% after 16 weeks. Compared to subjects without adverse events (51.8%), median inhibition was higher in subjects with one or more systemic adverse events (74.2%, P = 0.0203) or those with one or more local and systemic adverse events (77.1%, P = 0.0003). Conclusion: Nab induced by AZD1222 (AstraZeneca, UK) vaccination started to degrade shortly after the production period. Nab titers were lower in the elderly than in younger group during the degradation period. This seems to be because the degradation process of Nab is more pronounced in the elderly. This may explain why the frequency of breakthrough infections, disease severity, and mortality were higher in the elderly and may require revaccination to ensure robust immunity.
Abstract
Background: The kinetics of neutralizing antibodies against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) play an important role in evaluating vaccine efficacy and durability, herd immunity, additional vaccination, and prediction models of immune protection against coronavirus disease 2019. Materials and methods: Serum collection times were 4 and 8 weeks after 1st inoculation of AZD1222 (AstraZeneca, Cambridge, UK), and 2 and 16 weeks after 2nd inoculation with 12-week dosing intervals. Neutralizing antibody (Nab) titers were measured indirectly using commercially available R-FIND SARS-CoV-2 Neutralizing Antibody ELISA Kit (SG Medical Inc., Seoul, Korea). Possible influences of gender, age, and adverse events on neutralizing antibody titer were also investigated. Results: Nab titers (median inhibition %) started to decrease shortly after reaching peaks. This decrease was more pronounced in the elderly group (≥56 years) than in the young group (≤39 years) at 8 weeks (49.5% vs. 55.4%, P = 0.021) and 16 weeks (40.6% vs. 53.9%, P = 0.006) after the 1st and 2nd inoculation. And Nab titers were inversely correlated with age in the 8-week (r = -0.2091, P = 0.0284) and the 28-week group (r = -0.2811, P = 0.0029). Seropositive conversion of Nab reached 89.1% and 100% following 1st and 2nd inoculation. This 100% seropositivity was dropped sharply to 74.5% after 16 weeks. Compared to subjects without adverse events (51.8%), median inhibition was higher in subjects with one or more systemic adverse events (74.2%, P = 0.0203) or those with one or more local and systemic adverse events (77.1%, P = 0.0003). Conclusion: Nab induced by AZD1222 (AstraZeneca, UK) vaccination started to degrade shortly after the production period. Nab titers were lower in the elderly than in younger group during the degradation period. This seems to be because the degradation process of Nab is more pronounced in the elderly. This may explain why the frequency of breakthrough infections, disease severity, and mortality were higher in the elderly and may require revaccination to ensure robust immunity.
참고문헌 (29)
- "WHO coronavirus (COVID-19) dashboard"[URL]
- "The Gavi COVAX facility"[URL]
- Polack FP, "Safety and efficacy of the BNT162b2 mRNA Covid-19vaccine", N Engl J Med, 383, pp.2603~2615 (2020)
- Oliver SE, "The advisory committee on immunization practices’ interim recommendation for use of moderna COVID-19 vaccine-United States, December 2020", MMWR Morb Mortal Wkly Rep, 69, pp.1653~1656 (2021)
- Voysey M, "Safety and efficacy of the ChAdOx1 nCoV-19 vaccine(AZD1222)against SARS-CoV-2 : an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK", Lancet, 397, pp.99~111 (2021)
- SadoffJ, "Interim results of a phase 1-2a trial of Ad26. COV2. S Covid-19 vaccine", N Engl J Med, 384, pp.1824~1835 (2021)
- Lan J, "Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor", Nature, 581, pp.215~220 (2020)
- Lumley SF, "Antibody status and incidence of SARS-CoV-2 infection in health care workers", N Engl J Med, 384, pp.533~540 (2021)
- Deng W, "Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques", Science, 369, pp.818~823 (2020)
- Yu J, "DNA vaccine protection against SARS-CoV-2 in rhesus macaques", Science, 369, pp.806~811 (2020)
- Cruz-Teran C, "Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy", Adv Drug Deliv Rev, 169, pp.100~117 (2021)
- Bergwerk M, "Covid-19breakthrough infections in vaccinated health care workers", N Engl J Med, 385, pp.1474~1484 (2021)
- Bayart JL, "Waning of IgG, total and neutralizing antibodies 6months post-vaccination with BNT162b2 in healthcare workers", Vaccines(Basel), 9, pp.1092~ (2021)
- Xiong HL, "Robust neutralization assay based on SARS-CoV-2 S-protein-bearing vesicular stomatitis virus(VSV)pseudovirus and ACE2-overexpressing BHK21 cells", Emerg Microbes Infect, 9, pp.2105~2113 (2020)
- Tan CW, "A SARS-CoV-2 surrogate virus neutralization test based on antibodymediated blockage of ACE2-spike protein-protein interaction", Nat Biotechnol, 38, pp.1073~1078 (2020)
- Meyer B, "Validation and clinical evaluation of a SARS-CoV-2|surrogate virus neutralisation test(sVNT)", Emerg Microbes Infect, 9, pp.2394~2403 (2020)
- Bae Seongman, "Adverse Reactions Following the First Dose of ChAdOx1 nCoV-19 Vaccine and BNT162b2 Vaccine for Healthcare Workers in South Korea", Journal of Korean Medical Science, 36(17), pp.1~9 (2021), 대한의학회[DOI]
- Greinacher A, "Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination", N Engl J Med, 384, pp.2092~2101 (2021)
- Röltgen K, "Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome", Sci Immunol, 5, pp.eabe0240~ (2020)
- Müller L, "Age-dependent immune response to the biontech", Pfizer BNT162b2 coronavirus disease 2019 vaccination, 2021, pp.73, 2065~2072
- Dan JM, "Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection", Science, 371, pp.eabf4063~ (2021)
- 강유민, "Comparison of Antibody Response Elicited by ChAdOx1 and BNT162b2 COVID-19 Vaccine", Journal of Korean Medical Science, 36(46), pp.1~13 (2021), 대한의학회[DOI]
- Scobie HM, "Monitoring incidence of COVID-19 cases, hospitalizations, and deaths, by vaccination status-13 U. S. Jurisdictions, April 4-July 17, 2021", MMWR Morb Mortal Wkly Rep, 70, pp.1284~1290 (2021)
- Nam M, "Evaluation of humoral immune response after SARSCoV-2 vaccination using two binding antibody assays and a neutralizing antibody assay", Microbiol Spectr, 9, pp.e0120221~ (2021)
- Yun Sojeong, "Comparison of SARS-CoV-2 Antibody Responses and Seroconversion in COVID-19 Patients Using Twelve Commercial Immunoassays", Annals of Laboratory Medicine, 41(6), pp.577~587 (2021), 대한진단검사의학회[DOI]
- Terpos E, "Comparison of neutralizing antibody responses against SARS-CoV-2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222vaccine : Should the second AZD1222 vaccine dose be given earlier", Am J Hematol, 96, pp.E321~E324 (2021)
- Kim Si-Ho, "Adverse Events in Healthcare Workers after the First Dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 Vaccination: a Single Center Experience", Journal of Korean Medical Science, 36(14), pp.1~8 (2021), 대한의학회[DOI]
- Lee SW, "Anti-SARS-CoV-2 spike protein RBD antibody levels after receiving a second dose of ChAdOx1nCov-19(AZD1222)vaccine in healthcare workers : Lack of association with age, sex, obesity, and adverse reactions", Front Immunol, 12, pp.779212~ (2021)
- Zhuang CL, "Inflammation-related adverse reactions following vaccination potentially indicate a stronger immune response", Emerg Microbes Infect, 10, pp.365~375 (2021)